Please use this identifier to cite or link to this item:
Title: Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
Authors: Llorens, Franc
Hermann, Peter
Villar-Piqué, Anna
Diaz-Lucena, Daniela
Nägga, Katarina
Hansson, Oskar
Santana, Isabel 
Schmitz, Matthias
Schmidt, Christian
Varges, Daniela
Goebel, Stefan
Dumurgier, Julien
Zetterberg, Henrik
Blennow, Kaj
Paquet, Claire
Baldeiras, Inês 
Ferrer, Isidro
Zerr, Inga
Issue Date: 30-Jan-2020
Publisher: Springer Nature
Serial title, monograph or event: Nature Communications
Volume: 11
Issue: 1
Abstract: The clinical diagnosis of vascular dementia (VaD) is based on imaging criteria, and specific biochemical markers are not available. Here, we investigated the potential of cerebrospinal fluid (CSF) lipocalin 2 (LCN2), a secreted glycoprotein that has been suggested as mediating neuronal damage in vascular brain injuries. The study included four independent cohorts with a total n = 472 samples. LCN2 was significantly elevated in VaD compared to controls, Alzheimer's disease (AD), other neurodegenerative dementias, and cognitively unimpaired patients with cerebrovascular disease. LCN2 discriminated VaD from AD without coexisting VaD with high accuracy. The main findings were consistent over all cohorts. Neuropathology disclosed a high percentage of macrophages linked to subacute infarcts, reactive astrocytes, and damaged blood vessels in multi-infarct dementia when compared to AD. We conclude that CSF LCN2 is a promising candidate biochemical marker in the differential diagnosis of VaD and neurodegenerative dementias.
ISSN: 2041-1723
DOI: 10.1038/s41467-020-14373-2
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
I&D CNC - Artigos em Revistas Internacionais

Show full item record


checked on May 2, 2023

Page view(s)

checked on Sep 25, 2023


checked on Sep 25, 2023

Google ScholarTM




This item is licensed under a Creative Commons License Creative Commons